Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 2Neurofibromatoses 1NF1 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 6cemiplimab 3Cyclophosphamide 3temsirolimus 2palbociclib 2cediranib 2Therapeutics 2Radiotherapy 2Radiosurgery 2Psychiatric Rehabilitation 2Paclitaxel 2Oxaliplatin 2Nivolumab 2Methods 2Magnetic Resonance Spectroscopy 2Leucovorin 2Gemcitabine 2Fluorouracil 2Drug Therapy 2Docetaxel 2Cisplatin 2Capecitabine 2Biological Therapy 22,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1tanespimycin 1sonidegib 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × mirdametinib × Dermatologic × Clear all
NCT00147550 2013-09-13

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

Pfizer

Phase 1/2 Terminated
79 enrolled
BreastDermatologicGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡